Advertisement

Topics

Mylan's EpiPen still commands 25% of U.S. market thanks to PBM contracts - WSJ

11:19 EDT 7 Aug 2017 | Topix

The Wall Street Journal reports that Mylan remains in a leading position in the U.S. market for emergency allergy medications despite the higher cost of its EpiPen , commanding a market share of more than 25%. The company has been able to hold onto a healthy share of the business despite non-branded/competitive alternatives through its contracts with pharmacy benefit managers like Express Scripts and CVS Health, who prioritize EpiPen because the margins are better.

Original Article: Mylan's EpiPen still commands 25% of U.S. market thanks to PBM contracts - WSJ

NEXT ARTICLE

More From BioPortfolio on "Mylan's EpiPen still commands 25% of U.S. market thanks to PBM contracts - WSJ"

Quick Search
Advertisement
 

Relevant Topics

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...